UK Spinal Muscular Atrophy KOL Mapping

UK spinal muscular atrophy care runs through a small, nationally commissioned network rather than a broad hospital footprint. NHS England's Highly Specialised Services designate four regional networks (Manchester; Great Ormond Street Hospital and Evelina London Children's Hospital; Birmingham Children's Hospital and Alder Hey Children's Hospital; and the Royal Hospital for Children, Edinburgh) to manage SMA diagnosis, therapy selection, and ongoing monitoring. Gene-therapy administration sits within six NHS-designated centres nested inside those four networks, treating roughly 50 to 60 Zolgensma patients a year across the whole country. That concentration follows directly from NICE's Highly Specialised Technology appraisal route (HST15, 2021; expanded under HST24, 2023), which ties gene-therapy commissioning to a small number of accountable sites rather than open referral. Our KOL Universe gate (K1) starts by mapping this network structure before any single physician enters the workbook.

That structure changes how AXLRx tiers scientific and commercial influence in the UK. Great Ormond Street Hospital and the Bristol Institute of Child Health jointly run the prospective follow-up of the roughly 80 to 100 children treated with Zolgensma between 2021 and 2024, now aged two to five and being monitored for early attenuation signals ahead of the four-to-seven-year follow-up window. A centre running that kind of longitudinal cohort carries different scientific weight than one seeing occasional referred patients, and our Tier Classification gate (K2) scores that distinction directly, alongside HST15/TA755/TA588 guideline authorship and genetic-testing capability. Cure SMA UK's patient registry is the identification resource AXLRx cross-checks for the Type 4 adult-onset population still routed through general neurology rather than a dedicated SMA network. No named individual enters the workbook without a verification tag, checked against live publication and institutional-affiliation records, then marked Verified, Industry benchmark, or Requires client validation.

Every AXLRx KOL workbook is built from live NHS commissioning documentation, NICE decision records, and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.

UK SMA KOL sources: NHS England SMA commissioning policy 2023; NICE HST15 (2021) and HST24 (2023); NICE TA755 (2022) and TA588 (2019); and the institutional affiliations named in those decision documents and in SMA UK's patient organisation reporting.